<DOC>
	<DOCNO>NCT00002081</DOCNO>
	<brief_summary>To provide zalcitabine ( dideoxycytidine ; ddC ) use zidovudine ( AZT ) patient advance HIV infection . To observe serious toxicity population .</brief_summary>
	<brief_title>Open-Label Program Dideoxycytidine ( ddC ) Be Used Combination With Zidovudine ( AZT ) Treatment Advanced HIV Disease</brief_title>
	<detailed_description>Patients treat 1 2 dos ddC administer orally ( PO ) combination AZT administer PO ( patient unable tolerate dose AZT may receive low dose ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Concomitant use investigational compound prophylaxis treatment opportunistic infection treatment provide use compound ddCAZT consider safe . Patients must : Documented HIV infection OR document AIDSdefining opportunistic infection neoplasm . Previous AIDSdefining opportunistic infection , neoplasm , condition OR CD4 lymphocyte count equal le 300 cells/mm3 symptomatic ORCD4 lymphocyte count equal le 200 cells/mm3 asymptomatic . Patients must currently enrol must unable enter AIDS Clinical Trials Group ( ACTG ) , Community Programs Clinical Research AIDS ( CPCRA ) , control clinical program patient ineligibility , distance trial site , patient refusal . Patients currently enrol control clinical trial antiHIV compound may enter program meet end point require termination trial . Patients may coenrolled clinical program investigational compound test prophylaxis treatment opportunistic infection treatment provide program allows ddCAZT combination use , concomitant administration investigational drug ddCAZT consider safe investigator . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Any clinical laboratory toxicity abnormality , particularly presence history moderate severe peripheral neuropathy , would pose undue risk patient upon initiation ddCAZT treatment . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1992</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>